Prosecution Insights
Last updated: October 02, 2026
Application No. 18/777,115

ACTIVE ENERGY RAY CURABLE INKJET INK, METHOD FOR PRODUCING INKJET INK, INKJET RECORDING METHOD, AND INKJET RECORDING SYSTEM

Non-Final OA §103
Filed
Jul 18, 2024
Priority
Jul 28, 2023 — JP 2023-122941
Examiner
WHITELEY, JESSICA
Art Unit
Tech Center
Assignee
Konica Minolta Inc.
OA Round
1 (Non-Final)
89%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
96%
With Interview

Examiner Intelligence

Grants 89% — above average
89%
Career Allowance Rate
1359 granted / 1533 resolved
+28.6% vs TC avg
Moderate +7% lift
Without
With
+7.0%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 11m
Avg Prosecution
31 currently pending
Career history
1560
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
33.4%
-6.6% vs TC avg
§102
34.0%
-6.0% vs TC avg
§112
18.4%
-21.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1533 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-9 are rejected under 35 U.S.C. 103 as being unpatentable over Kasai (US 2009/0214797) as evidenced by, or, in the alternative, in view of Sekiguchi et al (US 2013/0010040). With regards to claim 1, Kasai teaches an inkjet ink composition that is radiation curable (abstract) that contains a pigment (abstract), a dispersant (0007), and additives (0458). Kasai teaches the dispersant to be a compound formed from the reaction of an amine and hydroxystearic acid (0008) and the composition to include pyridine (0255). Kasai does not teach the addition of a gelling agent. Sekiguchi teaches that hydroxystearic acid acts as a gelling agent (0111 table 1) and Kasai teaches the presence of this compound in the composition. The broadest reasonable interpretation of the claims reads that the gelling agent and the hydroxy fatty acid can be the same compound. Therefore, because Kasai teaches the inclusion of the hydroxystearic acid, it teaches the use of a gelling agent. Sekiguchi teaches an inkjet ink (abstract) that contains a pigment (0061) and a gelling agent (0033) and teaches the motivation for adding the gelling agent to be because it employs a phase transition of the ink before the ink excessively permeates the substrate (0033). Kasai and Sekiguchi are analogous in the art of inkjet ink compositions. In light of the benefit above, it would have been obvious to one skilled in the art prior to the effective filing date of the present invention to add the gelling agent of Sekiguchi. With regards to claim 2, Kasai teaches the polymer to be copolymer of (meth)acrylic acids and a pyridine (0171). With regards to claim 3, Kasai is silent on the amine value of the hydroxystearic acid. However both Kasai and the art use 12-hydroxystearic acid, and therefore, this compound is read to have the claimed amine value. With regards to claims 4 and 5, Kasai is silent on the amounts of the pyridine compound and the hydroxystearic acid. However, generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by prior art unless there is evidence indicating such concentration or temperature is critical. See MPEP 2144.05. Further, where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 124 (CCPA 1955). In this case, one skilled in the art prior to the effective filing date of the present invention would know to alter the amounts of these two compounds in order to achieve the desired gelability and amounts of dispersant created in the reaction (hydroxystearic acid) and the viscosity of the composition (pyridine compound). With regards to claim 6, Kasai teaches the addition of black or magenta pigments (0049) With regards to claim 7, Kasai teaches the process of producing the ink to include mixing the components including the pigment and dispersant (0769) with the remaining components (0771). With regards to claim 8, Kasai teaches the ink to be printed at a temperature of 25 to 80°C (0514) and the substrate to be room temperature (reading on 25°C) (0514). With regards to claim 9, Kasai teaches the composition to be applied to a substrate (0053). Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. The following reference teaches the claimed compound of claim 1 but does not include the exact dispersant or gelling agent: Nakamura et al (US 2009/0169765); and the following reference teaches the dispersant as claimed with motivation for using it: Fujimatsu et al (JP 2002294121). Any inquiry concerning this communication or earlier communications from the examiner should be directed to JESSICA WHITELEY whose telephone number is (571)272-5203. The examiner can normally be reached 8 - 5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joseph Del Sole can be reached at 5712721130. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JESSICA WHITELEY/Primary Examiner, Art Unit 1763
Read full office action

Prosecution Timeline

Jul 18, 2024
Application Filed
Sep 01, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12748349
PHOTOSENSITIVE RESIN COMPOSITION AND DISPLAY DEVICE INCLUDING THE SAME
3y 10m to grant Granted Sep 29, 2026
Patent 12747363
ACTIVE ENERGY RAY-CURABLE INKJET INK COMPOSITION
3y 4m to grant Granted Sep 29, 2026
Patent 12741414
PARTICULATE BUILD MATERIALS FOR THREE-DIMENSIONAL PRINTING
3y 6m to grant Granted Sep 22, 2026
Patent 12735380
SYNTHESIS OF PARA-ALKYLATED SYRINGYL (METH)ACRYLATE DERIVATIVES AND PHOTOPOLYMERIZABLE COMPOSITIONS FOR ADDITIVE MANUFACTURING IN DENTAL APPLICATIONS
3y 8m to grant Granted Sep 15, 2026
Patent 12735381
CARDANOL-BASED REACTIVE DILUENTS AND THEIR USE AND PREPARATION
3y 0m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
89%
Grant Probability
96%
With Interview (+7.0%)
1y 11m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1533 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month